Table 4 Univariate and multivariate Cox regression of MYBL2 for overall survival in glioma
From: Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma
| Â | OS | |||
|---|---|---|---|---|
Variable | Univariate analysis | Multivariate analysis | ||
| Â | HR (95% CI) | P-value | HR (95% CI) | P-value |
Age (year) | ||||
 <45 vs. ≥45 | 0.874 (0.488-1.567) | 0.652 | 0.873 (0.474-1.606) | 0.873 |
Gender | ||||
 Female vs. male | 1.038 (0.617-1.746) | 0.889 | 1.021 (0.590-1.767) | 0.941 |
Clinical Stage | ||||
 III-IV vs. I-II | 1.833(1.395-2.409) | <0.001 | 0.360 (0.193 -0.670) | <0.05 |
Tumor Location | ||||
 Parietal vs. Frontal | 1.413 (0.715-2.790) | 0.32 | 0.731 (0.324 -1.650) | 0.45 |
 Temporal vs. Frontal | 1.173 (0.652-2.110) | 0.594 | 0.995 (0.517-1.914) | 0.966 |
 Others vs. Frontal | 0.605 (0.297-1.232) | 0.166 | 0.335 (0.308-1.493) | 0.301 |
MYBL2 Expression | ||||
 Low vs. high | 3.619 (2.075-6.313) | <0.001 | 0.354 (0.193-0.650) | <0.05 |